An international research team led by the Helmholtz Center for Infection Research (HZI) has discovered a new strategy used by ...

SAN FRANCISCO — Patients with bronchiectasis and a Pseudomonas aeruginosa infection receiving gremubamab, a bispecific monoclonal antibody, vs. placebo had several improved outcomes, according ...

Journal of Infection (2016). [4] Pseudomonas aeruginosa manipulates redox and iron homeostasis of its microbiota partner Aspergillus fumigatus via phenazines. Scientific Reports (2015).

Colistin became available for clinical use in the 1960s, but was replaced in the 1970s with other antibiotics owing to its toxicity. [1, 4, 13] There are two forms of colistin available in the ...

The human pathogen Pseudomonas aeruginosa is the leading cause of hospital-acquired infections and, moreover, is resistant to commonly used antibiotics. P. aeruginosa uses the cell-to-cell ...

1-Hydroxyphenazine (1-HP) is a virulence factor produced by Pseudomonas aeruginosa. In this study, supercoiled plasmid DNA was employed as an analytical tool for the detection of ROS generation ...

Biofilms are physical barriers composed of extracellular polymeric substances (EPS) that enable planktonic bacteria to resist host responses and antibacterial treatments, complicating efforts to clear ...

P. aeruginosa- associated chronic lung infections are one of the main contributors to loss of pulmonary function, which is the primary cause of death in patients with CF (3, 4). Based on the Cystic ...

Despite intensive research efforts, the aetiology of the majority of chronic lung diseases (CLD) in both, children and adults, remains elusive. Current therapeutic options are limited, providing only ...

Risk factors for bacterial colonisation/infection of the airways include smoking, severity of airway obstruction and/or inflammation of the airways. 2 Moreover, bacterial colonisation/infection of the ...